Often known as China's Warren Buffett, Guo Guangchang prefers to be his student instead. His mysterious disappearance last year raised many...

The U.S. Food and Drug Administration on Wednesday approved a radical new one-time treatment from the Swiss drugmaker, weeks earlier than e...

With Kite, Gilead will gain cancer therapies and experimental drugs in one of the most promising fields in oncology, in addition to its hep...

The billionaire co-founder of the private equity firm apologised for cracking a joke during a charged company-wide meeting to discuss sweep...

As dust settles on Dalal Street after a nerve-wrecking runup to the Union Budget of 2016, foreign institutional investors are back with a b...

ETMarkets.com data showed as many as 121 stocks hit their 52-week lows earlier in the year only to scale their lifetime highs later.

Here's a look at a bunch of investors who despite the tremendous influence they wield on the stock market are not thrilled with the limelig...

A number of funds also took positions in pharmaceuticals stock Perrigo, including Kyle Bass of Hayman Capital.

According to Nasdaq, the stock price of ISIS Pharmaceuticals crossed above its 200-day moving average for the first time since early spring.

ISIS Pharmaceuticals, a $4.3 billion biotech firm surged 10% today, and it's up 43% in the last three months.

Indian markets are expected to trade in a range. Here is a list of ten stocks which are likely to be in focus today.